Buffalo Biolabs, LLC (BBL) and Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that because of maturation of CBLI’ development pipeline and a reduced need for certain services, it has transferred laboratory and preclinical services personnel to BBL, an entity affiliated with one of the CBLI’s co-founders, Dr. Andrei Gudkov, PhD, DSci. CBLI has executed a service agreement providing for continued access to BBL team on an as-needed basis. As part of the transfer, Dmitry Tyomkin, MBA has agreed to join BBL as President and CEO. Previously, Dmitry served as President and CEO of Panacela Labs, a majority-owned subsidiary of Cleveland Biolabs.
Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Buffalo, NY based Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters in Buffalo Niagara Medical Campus.